53
Participants
Start Date
December 17, 2021
Primary Completion Date
April 30, 2025
Study Completion Date
April 30, 2026
Tucatinib
300 mg orally twice daily
Pertuzumab
Initial loading: 840 mg Maintenance: 420 mg, 3-weekly
Trastuzumab
"Intravenous formulation :~Initial loading: 8 mg/kg Maintenance: 6 mg/kg, 3-weekly~Subcutaneous formulation:~600 mg (fixed dose regardless of patient's body weight), 3-weekly"
Hormone therapy
Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)
Pertuzumab/ Trastuzumab
"Initial loading:~1200 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight)~Maintenance:~600 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight), 3-weekly"
Clinique Victor Hugo, Le Mans
Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers
Centre Francois Baclesse, Caen
Centre Georges François Leclerc, Dijon
Centre Leon Berard, Lyon
Hôpital privé Jean Mermoz, Lyon
CRLC Val d'Aurelle, Montpellier
Centre Antoine Lacassagne, Nice
CARIO - Centre Armoricain Radiothérapie Imagerie Médicale et Oncologi, Plérin
Centre Hospitalier Annecy Genevois, Pringy
Institut Jean Godinot, Reims
Centre Henri Becquerel, Rouen
Institut Claudius Regaud, Toulouse
Centre Hospitalier Universitaire de Tours, Tours
Gustave Roussy, Villejuif
Seagen Inc.
INDUSTRY
ARCAGY/ GINECO GROUP
OTHER
UNICANCER
OTHER